证券代码：300238 证券简称：冠昊生物 公告编号：2022-032 冠昊生物科技股份有限公司 2022 年第三季度报告 冠昊生物科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大 遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度报告是否经过审计 □是 否 1 冠昊生物科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □适用 不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益项 目的情况说明 单位：元 2 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥202,877,076.02, a decrease of 22.68% compared to ¥262,400,078.08 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was -¥243,985,842.23, a decline of 706.56% from ¥40,224,480.64 in the previous year[23]. - The net cash flow from operating activities was ¥37,373,341.16, down 47.76% from ¥71,535,873.64 in the same period last year[23]. - The basic earnings per share were -¥0.92, a decrease of 713.33% compared to ¥0.15 in the previous year[23]. - Total assets at the end of the reporting period were ¥794,724,907.81, a reduction of 27.67% from ¥1,098,737,109.35 at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company were ¥543,819,534.75, down 30.63% from ¥783,920,552.56 at the end of the previous year[23]. - The weighted average return on net assets was -36.75%, a decrease of 42.12% from 5.37% in the previous year[23]. - The company achieved operating revenue of 202.88 million yuan, a decrease of 22.68% compared to the same period last year[34]. - The net profit attributable to shareholders of the listed company was -244.99 million yuan, a decline of 706.56% year-on-year, primarily due to inventory and goodwill impairment losses amounting to 276.42 million yuan[34]. - The company reported a significant asset impairment loss of CNY -276,805,715.91 during the first half of 2022[140]. Revenue and Cost Analysis - Operating costs decreased by 21.17% to ¥48,656,735.59 from ¥61,726,520.78, reflecting the decline in revenue[50]. - The company reported a comprehensive income total of CNY -243,273,320.32 for the first half of 2022, contrasting with CNY 31,909,380.26 in the same period of 2021[144]. - The total operating costs decreased to CNY 174,223,359.18, down 21.8% from CNY 222,836,824.95 in the same period last year[139]. - The company experienced a significant increase in sales expenses, which were CNY 24,435,333.26, down 47.3% from CNY 46,289,607.74 in the previous year[143]. Research and Development - Research and development investment increased by 53.24% to ¥30,572,829.58, indicating a focus on key R&D projects[50]. - The company has authorized 8 new domestic patents during the reporting period, bringing the total to 118, including 85 invention patents[42]. - Research and development expenses increased to CNY 24,295,614.86, up 26.5% from CNY 19,207,082.17 in the previous year[140]. - The company is actively involved in technology development and consulting services, positioning itself as a key player in the biotechnology industry[164]. Market and Product Development - The company is expanding its pharmaceutical platform with the product Benvimode, which shows promising results in treating autoimmune diseases[32]. - The company plans to develop new products using a novel biological materials platform, focusing on a pipeline that includes research, clinical trials, regulatory submissions, and market launch[70]. - New product launches are expected to occur in the second half of 2022, aimed at capturing additional market share[154]. - The company plans to expand its market presence and invest in new product development to drive future growth[154]. Cash Flow and Liquidity - Cash and cash equivalents at the end of the reporting period amounted to ¥159,233,978.93, representing 20.04% of total assets, an increase of 5.54% compared to the previous year[55]. - The cash inflow from operating activities totaled CNY 224,527,825.50, a decrease of 19.6% from CNY 279,475,178.96 in the first half of 2021[147]. - The total cash flow from financing activities was -¥28,088,494.74, a decrease from -¥59,453,770.59 in the first half of 2021[150]. - The company reported a net cash flow from investing activities of -¥474,136.10, compared to a positive cash flow of ¥3,080,097.11 in the first half of 2021[149]. Corporate Governance and Social Responsibility - The company ensures the protection of shareholder and creditor rights through transparent governance and effective communication mechanisms[81]. - The company maintains a commitment to social responsibility, focusing on innovation in regenerative medicine to enhance human health and quality of life[80]. - The company emphasizes a commitment to employee rights and welfare, implementing comprehensive management systems for labor contracts, salary, assessments, and benefits[83]. - The company actively engages in social responsibility initiatives, contributing to local and national development while promoting health education and disease prevention[84]. Risks and Challenges - The company faces risks related to policy changes in the medical device industry, which could impact sales regions and pricing[68]. - The development and approval process for new medical implant products is lengthy, which poses risks to the timely launch of new products[69]. - The company has a significant overseas asset in Hong Kong valued at ¥47,863,437.53, representing 9.48% of the company's net assets, which is subject to potential impairment risks[56]. Shareholder Information - The total number of shares after the recent changes is 265,155,701, with 99.99% being unrestricted shares[113]. - The largest shareholder, Guangdong Zhiguang Biotechnology Co., Ltd., holds 55,044,822 shares, accounting for 20.76% of the total shares[117]. - The total number of common stock shareholders at the end of the reporting period is 31,024[117]. - The company reported a 29.50% investor participation rate in the annual general meeting held on May 18, 2022[74]. Compliance and Audit - The semi-annual financial report was not audited[92]. - The financial statements comply with the requirements of the Accounting Standards for Business Enterprises, reflecting the company's financial position as of June 30, 2022, and the operating results and cash flows for the first half of 2022[168]. - The company did not experience any major litigation or arbitration matters during the reporting period[94].

Financial Performance - The company's revenue for Q1 2022 was ¥122,927,958.21, a decrease of 4.29% compared to ¥128,441,392.59 in the same period last year[5] - Net profit attributable to shareholders increased by 19.36% to ¥21,779,567.39 from ¥18,247,093.30 year-on-year[5] - The net profit after deducting non-recurring gains and losses rose by 25.08% to ¥20,159,987.17 compared to ¥16,117,136.00 in the previous year[5] - Total operating revenue for Q1 2022 was RMB 122,927,958.21, a decrease of 4.0% compared to RMB 128,441,392.59 in the same period last year[21] - The company's net loss for Q1 2022 was RMB 43,642,413.46, an improvement from a net loss of RMB 65,421,980.87 in the previous year[19] - The net profit for Q1 2022 was CNY 21,363,230.14, an increase of 32.4% compared to CNY 16,145,942.21 in Q1 2021[22] - The operating profit for the quarter was CNY 27,587,289.56, up from CNY 23,634,014.51, reflecting a growth of 16.5%[22] - The company reported a total comprehensive income of CNY 20,843,673.76, compared to CNY 16,544,859.18 in Q1 2021, marking an increase of 25.8%[23] - Basic and diluted earnings per share were both CNY 0.08, an increase from CNY 0.07 in the previous year[23] Cash Flow and Investments - The company's cash flow from operating activities decreased by 16.72% to ¥24,690,382.91 from ¥29,648,073.35 in the same period last year[10] - The cash flow from operating activities was CNY 24,690,382.91, down 16.5% from CNY 29,648,073.35 in the same period last year[26] - The company incurred a net cash outflow from investing activities of CNY 2,369,821.21, compared to a net inflow of CNY 3,652,612.25 in the previous year[26] - The company experienced a 96.97% decrease in cash flow from financing activities, resulting in a net cash increase of ¥17,716,277.00 compared to a decrease of ¥24,061,655.30 in the previous year[10] - Cash and cash equivalents at the end of Q1 2022 amounted to RMB 177,024,470.99, an increase of 11.0% from RMB 159,308,193.99 at the beginning of the year[16] - The cash and cash equivalents at the end of the period totaled CNY 177,024,470.99, an increase from CNY 132,140,402.93 at the end of Q1 2021[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,108,065,686.84, an increase of 0.85% from ¥1,098,737,109.35 at the end of the previous year[5] - Total assets as of March 31, 2022, were RMB 1,108,065,686.84, a slight increase from RMB 1,098,737,109.35 at the beginning of the year[19] - Total liabilities decreased to RMB 339,060,131.15 from RMB 350,575,227.44, a reduction of 3.9%[18] - The total equity attributable to shareholders increased to RMB 805,180,563.59 from RMB 783,920,552.56, reflecting a growth of 2.0%[19] Research and Development - Research and development expenses increased by 40.72% to ¥9,770,941.24 from ¥6,943,468.85 year-on-year, indicating a significant investment in R&D[9] - Research and development expenses increased to RMB 9,770,941.24, up 40.7% from RMB 6,943,468.85 in the previous year[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,000[11] Other Operating Income - The company reported a significant increase in government subsidies, contributing to a 241.74% rise in other operating income to ¥132,035.24[9] Inventory and Receivables - Accounts receivable rose to RMB 114,965,319.30, compared to RMB 106,706,485.37 at the start of the year, reflecting a growth of 7.6%[16] - Inventory decreased to RMB 122,972,490.67, down 12.5% from RMB 140,548,422.60 at the beginning of the year[17] Operating Costs - Total operating costs for Q1 2022 were RMB 95,647,842.56, down 10.5% from RMB 106,850,280.30 in Q1 2021[21] - The total operating expenses were CNY 101,503,768.18, slightly down from CNY 103,125,718.28 in Q1 2021[26] Market Activity - The company did not report any significant new product launches or market expansions during this quarter[27]

Financial Performance - Guanhao Biotech reported a total revenue of CNY 1.2 billion in 2021, representing a year-on-year increase of 15%[17]. - The company has set a revenue target of CNY 1.5 billion for 2022, reflecting a growth forecast of 25%[17]. - The company's operating revenue for 2021 was CNY 488,981,886.96, representing an increase of 11.91% compared to 2020[21]. - The net profit attributable to shareholders for 2021 was CNY 73,687,006.12, a significant increase of 58.14% from the previous year[21]. - The gross profit margin for 2021 was reported at 60%, slightly down from 62% in 2020 due to increased raw material costs[17]. - Operating profit reached CNY 81.56 million, up 81.38% year-on-year[49]. - Total profit amounted to CNY 82.06 million, reflecting an increase of 82.85% from the previous year[49]. - The company reported a basic earnings per share of CNY 0.28, which is a 55.56% increase from CNY 0.18 in 2020[21]. - The weighted average return on equity for 2021 was 9.73%, up from 6.46% in 2020[21]. Research and Development - The company plans to invest CNY 200 million in R&D for new regenerative medical products in 2022[17]. - The company reported R&D investment of ¥49,176,170.36 in 2021, representing 10.06% of operating revenue, an increase from 7.91% in 2020[73]. - The company is focusing on developing innovative therapies for autoimmune diseases, with a new product expected to enter clinical trials in 2023[17]. - The company is actively involved in the development of stem cell therapies, supported by national policies aimed at promoting this field[38]. - The company aims to enhance its R&D capabilities and increase investment in innovative materials and cell therapy technologies, focusing on producing and developing new products[95]. - The company is conducting preclinical studies on mesenchymal stem cell therapy, focusing on various diseases including dermatology and hematology[72]. - The company has established a technology system for the preparation of immune and stem cells that meets GMP standards, and has received quality certification from the National Institute for Food and Drug Control[39]. - The company has been granted 5 invention patents in its cell therapy sector in 2021, indicating a strong focus on innovation[39]. Market Expansion - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2022[17]. - User data indicates a 25% increase in the number of hospitals using Guanhao's products, reaching a total of 500 hospitals by the end of 2021[17]. - The company aims to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[126]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share within the next three years[128]. Product Development - The company has launched a new line of bio-materials, which is expected to contribute CNY 300 million in revenue in 2022[17]. - The company introduced two new products in Q4 2021, which are anticipated to contribute an additional 200 million RMB in revenue[122]. - The product "Benvimod" is a first-in-class drug for treating inflammatory and autoimmune diseases, recognized as a significant achievement in national drug creation projects[43][44]. - The company aims to register and commercialize its biodegradable tear duct plugs for dry eye treatment, enhancing its ophthalmology product line[72]. - The company is advancing the registration of Benvimod for ulcerative colitis, expanding its pharmaceutical product offerings[72]. Acquisitions and Partnerships - Guanhao has successfully completed the acquisition of a local biotech firm for CNY 100 million to enhance its product portfolio[17]. - A strategic acquisition of a local biotech firm is expected to enhance the company's product portfolio and increase market competitiveness[121]. - The company has established a partnership with a leading healthcare provider, aiming to improve distribution channels and increase sales by 15%[128]. Financial Management - The company has not declared any cash dividends for 2021, opting to reinvest profits into business growth[8]. - The total cash inflow from investment activities surged by 5,751.05% to CNY 16.53 million in 2021, compared to CNY 0.28 million in 2020[77]. - The company reported a significant increase in R&D expenses, totaling ¥46.62 million, which is a 36.11% increase year-on-year due to multiple new R&D projects[69]. - The company’s total operating costs decreased by 12.33% to ¥16.50 million in the medical device segment[65]. Governance and Compliance - The company maintains complete independence from its controlling shareholders in terms of business, personnel, assets, and finances, ensuring autonomous operational capabilities[116]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective decision-making and supervision[106]. - The company emphasizes the importance of information disclosure and investor relations management, adhering to relevant regulations and ensuring accurate and timely information release[113]. - The company has established multiple communication channels with investors, including dedicated phone lines and email, to enhance engagement and understanding of its business and investment value[113]. Employee Management - The total number of employees at the end of the reporting period was 557, with 166 in the parent company and 391 in major subsidiaries[146]. - The company has established a comprehensive training system to enhance employees' skills and support business objectives[149]. - The company has not proposed any cash dividend distribution plan during the reporting period despite having positive distributable profits[150]. - The company has implemented various employee training programs to enhance professional skills and overall capabilities[162]. Social Responsibility - The company actively engages in social responsibility initiatives, contributing to local development and participating in health education activities[165]. - The company emphasizes a harmonious work environment, focusing on employee rights and benefits, including comprehensive social insurance and various welfare programs[162]. - The company is focused on creating a low-carbon, resource-saving enterprise to align with national goals for carbon neutrality[164].

Revenue and Profit - Revenue for Q3 2021 was CNY 109,590,960.17, a decrease of 5.07% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2021 reached CNY 19,554,289.44, an increase of 97.64% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 12,071,544.99, up 63.28% from the previous year[5]. - Basic earnings per share for Q3 2021 was CNY 0.07, representing a 75.00% increase year-on-year[5]. - The net profit for Q3 2021 was CNY 48,089,015.65, an increase of 33.1% compared to CNY 36,138,285.57 in Q3 2020[21]. - The total comprehensive income for the period was CNY 46,801,724.79, compared to CNY 34,199,648.53 in the prior year, marking an increase of 36.9%[22]. - The company achieved a total profit of CNY 67,204,965.76, compared to CNY 49,336,996.86 in Q3 2020, reflecting a growth of 36.2%[21]. Cash Flow and Operating Activities - Cash flow from operating activities for the year-to-date period was CNY 91,393,514.30, an increase of 39.03%[5]. - The cash flow from operating activities generated a net amount of CNY 91,393,514.30, compared to CNY 65,734,489.80 in the previous year, indicating a year-over-year increase of 38.9%[24]. - The company reported a total revenue from operating activities of CNY 66,667,108.58, up from CNY 49,177,931.79 in the same period last year, reflecting a growth of 35.7%[21]. Assets and Liabilities - Total assets at the end of Q3 2021 were CNY 1,136,804,048.31, a slight increase of 0.18% from the end of the previous year[5]. - As of September 30, 2021, total assets were RMB 1,136,804,048.31, slightly up from RMB 1,134,727,829.20 at the end of 2020[19]. - Current assets totaled RMB 448,480,862.59, an increase from RMB 438,034,052.02 at the end of 2020[17]. - Total liabilities decreased to RMB 372,844,609.04 from RMB 418,068,165.87 at the end of 2020, indicating a decline of 10.8%[18]. - Current liabilities reached CNY 302.70 million, with short-term borrowings at CNY 102.88 million and accounts payable at CNY 3.01 million[28]. - Non-current liabilities totaled CNY 115.37 million, including long-term borrowings of CNY 54.60 million and deferred income of CNY 49.45 million[29]. - The total liabilities and equity combined were CNY 1,134.73 million, consistent with total assets[29]. Research and Development - R&D expenses for the year-to-date period were CNY 33,891,458.43, a 40.73% increase compared to the same period last year, indicating increased investment in innovation[10]. - Research and development expenses increased to RMB 33,891,458.43, representing a rise of 40.5% compared to RMB 24,082,618.24 in the previous year[19]. Shareholders' Equity - The company’s total equity attributable to shareholders increased by 7.97% to CNY 788,456,314.40 compared to the end of the previous year[5]. - Shareholders' equity stood at CNY 716.66 million, with a capital reserve of CNY 599.02 million[29]. Tax and Expenses - The company reported a significant increase in tax expenses, totaling CNY 19,115,950.11, up 44.83% due to higher overall profits[11]. - The total operating expenses were CNY 329,023,162.31, slightly up from CNY 323,243,810.13 in the same period last year[24]. - Total operating costs amounted to RMB 322,307,582.50, up 16.3% from RMB 276,953,664.43 year-on-year[19]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[21].

Financial Performance - The company's operating revenue for the reporting period was ¥262,400,078.08, representing a 28.87% increase compared to ¥203,611,983.94 in the same period last year[21]. - The net profit attributable to shareholders was ¥40,224,480.64, reflecting a 49.16% increase from ¥26,966,857.33 year-over-year[21]. - The net profit after deducting non-recurring gains and losses was ¥31,881,254.58, up 62.42% from ¥19,628,680.96 in the previous year[21]. - The net cash flow from operating activities was ¥71,535,873.64, a significant increase of 64.14% compared to ¥43,582,812.43 in the same period last year[21]. - The total assets at the end of the reporting period were ¥1,159,925,796.81, which is a 2.22% increase from ¥1,134,727,829.20 at the end of the previous year[21]. - The net assets attributable to shareholders increased by 5.32% to ¥769,114,192.52 from ¥730,267,783.85 at the end of the previous year[21]. - The company achieved operating revenue of 262.40 million yuan, a year-on-year increase of 28.87%, and a net profit attributable to shareholders of 40.22 million yuan, up 49.16% year-on-year[40]. - The total comprehensive income attributable to the parent company was ¥39.15 million, compared to ¥28.76 million in the same period last year, marking a 36% increase[146]. - The company reported a net profit of CNY 16,084,465 for the first half of 2021, reflecting a significant improvement in profitability[169]. Research and Development - The company continues to focus on innovation in the regenerative medicine industry, with a range of self-developed biomedical materials already on the market[28]. - The company has applied for 5 new invention patents and received 6 new domestic invention patents, bringing the total to 121 authorized patents[46]. - Research and development expenses amounted to ¥19,951,298.03, reflecting a 13.07% increase as the company continues to invest in maintaining and expanding its technological leadership[56]. - The company is actively pursuing clinical research collaborations for mesenchymal stem cell projects, enhancing its research capabilities in regenerative medicine[46]. - The company is committed to continuous R&D investment and aims to enhance its technological advantages in regenerative medical implants[79]. - The company has invested in research and development for new medical materials and technologies, aiming to enhance its product offerings[172]. Market Position and Strategy - The company aims to enhance its rapid industrialization capabilities through its wholly-owned subsidiary, which is dedicated to creating a professional incubation platform for life and health innovation[30]. - The company is positioned to benefit from ongoing policy support for the medical device industry, including centralized procurement and monitoring of key products[33]. - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[161]. - The company is actively pursuing opportunities for mergers and acquisitions to enhance its competitive edge in the market[172]. - The company aims to leverage its strong R&D capabilities and innovative technologies to drive rapid industrialization and market expansion[53]. Social Responsibility and Governance - The report includes a commitment to social responsibility and environmental governance[23]. - The company emphasizes social responsibility, focusing on health and dignity through innovative medical products and technologies[91]. - The company is committed to green operations, aiming for low-carbon development and improved resource utilization efficiency[91]. - The company is not classified as a key pollutant discharge unit by environmental protection authorities[90]. - There were no significant safety production accidents or environmental pollution incidents during the reporting period[90]. Financial Management and Reporting - The financial report is guaranteed to be true, accurate, and complete by the company’s responsible persons[3]. - The semi-annual financial report has not been audited[99]. - The company prepares its financial statements based on the going concern assumption and adheres to the accounting standards issued by the Ministry of Finance[174]. - The financial statements accurately reflect the company's financial position as of June 30, 2021, and its operating results and cash flows for the first half of 2021[175]. - The company confirms its ability to continue as a going concern for at least 12 months from the reporting date[174]. Shareholder Information - The total number of shares after the recent changes is 265,155,701, with 99.99% being unrestricted shares[118]. - The company has 35,936 ordinary shareholders at the end of the reporting period[121]. - Guangdong Zhiguang Biotechnology Co., Ltd. holds 20.76% of the shares, totaling 55,044,822 shares, which are pledged and frozen[121]. - The company’s major shareholder, Guangdong Zhiguang Biotechnology Co., Ltd., remains unchanged as the controlling entity[126]. Risks and Challenges - The company faces risks related to policy changes in the medical device industry, which could impact sales regions and prices[78]. - The company reported a net loss from investment income of ¥2,569,954.51, accounting for -5.50% of total profit, due to losses from joint ventures[59]. - The company reported a net loss of 7,264 million yuan for the current period, indicating a significant financial challenge[162].

Financial Performance - The company's operating revenue for Q1 2021 was ¥128,441,392.59, representing a 37.59% increase compared to ¥93,348,010.41 in the same period last year[8]. - Net profit attributable to shareholders was ¥18,247,093.30, up 57.99% from ¥11,549,674.96 year-on-year[8]. - The net profit after deducting non-recurring gains and losses was ¥16,117,136.00, an increase of 83.58% compared to ¥8,779,539.66 in the previous year[8]. - Basic earnings per share increased to ¥0.07, a 75.00% rise from ¥0.04 in the previous year[8]. - The company reported a total comprehensive income of ¥16,544,859.18 for Q1 2021, compared to ¥11,701,532.94 in the previous year, representing an increase of approximately 41.5%[48]. - The net profit for Q1 2021 was CNY 8,648,800.21, representing a 44.6% increase compared to CNY 5,968,446.88 in Q1 2020[52]. - Operating profit for the period was CNY 11,410,214.21, up from CNY 6,724,739.94 in the same period last year, indicating a growth of 69.9%[52]. - The company's gross profit margin improved, with operating profit for Q1 2021 at ¥23,634,014.51, up from ¥14,353,275.79 in the previous year, marking an increase of about 64.5%[47]. Cash Flow - The net cash flow from operating activities was ¥29,648,073.35, a significant improvement of 279.00% from -¥16,563,348.15 in the same period last year[8]. - Cash inflow from operating activities totaled CNY 132,773,791.63, compared to CNY 121,379,048.22 in the previous year, reflecting an increase of 9.8%[54]. - The cash outflow for operating activities was CNY 103,125,718.28, down from CNY 137,942,396.37 in the same period last year, indicating a decrease of 25.2%[55]. - The company's cash flow from investing activities increased by 452.56% year-on-year, due to the recovery of long-term equity investments and fixed assets[21]. - The cash flow from investing activities generated a net inflow of CNY 3,652,612.25, recovering from a net outflow of CNY 1,036,038.94 in the previous year[55]. - The net cash flow from investment activities was 3,551,067.09 CNY, a decrease of 49,078.99 CNY compared to the previous period[59]. - The company's cash and cash equivalents decreased from CNY 156,202,058.23 to CNY 132,140,402.93, a decline of about 15.4%[37]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,121,378,540.53, a decrease of 3.63% from ¥1,134,727,829.20 at the end of the previous year[8]. - Total liabilities decreased from CNY 418,068,165.87 to CNY 388,674,018.02, a reduction of approximately 7.0%[39]. - The company's short-term borrowings decreased significantly from CNY 102,876,698.53 to CNY 72,593,884.72, a reduction of approximately 29.4%[39]. - Current assets decreased from CNY 438,034,052.02 on December 31, 2020, to CNY 411,838,188.72 on March 31, 2021, representing a decline of approximately 6.0%[37]. - Total equity attributable to the parent company increased from CNY 730,267,783.85 to CNY 747,610,845.45, reflecting an increase of about 2.5%[40]. - The total liabilities of the company stood at ¥466,215,965.84, with total equity amounting to ¥849,247,516.65 as of the end of Q1 2021[46]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,644[12]. - The largest shareholder, Guangdong Zhiguang Biotechnology Co., Ltd., held 20.76% of the shares, amounting to 55,044,822 shares, with a portion of these shares frozen[12]. - The company’s controlling shareholder has 41,394,822 shares frozen, accounting for 15.61% of the total share capital, but this will not significantly impact the company's operations[24]. Strategic Focus and Operations - The company plans to deepen its focus on the regenerative medicine field and enhance its own product brand as part of its 2021-2025 strategic plan[23]. - The company reported a commitment to avoid engaging in any competitive activities with its subsidiaries, ensuring no direct or indirect competition with its products and services[28]. - The company has a strict adherence to its commitments regarding non-competition, with a promise to compensate for any losses incurred due to breaches of these commitments[29]. - The company is focused on maintaining its competitive edge by avoiding any potential conflicts of interest with its controlling shareholders[29]. - The company has committed to not utilizing its position to gain preferential treatment in business dealings, ensuring fair market practices[29]. Compliance and Governance - There were no violations of external guarantees during the reporting period, indicating a stable financial position[31]. - The company confirmed that there were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[32]. - The financial statements indicate a commitment to transparency and compliance with regulatory requirements, with no significant changes in net profit forecasted[30]. - The company has implemented measures to ensure fair and equitable treatment in any related party transactions, adhering to established decision-making processes[28]. Employee Compensation and Expenses - The company experienced a 64.18% decrease in employee compensation payable at the end of the reporting period compared to the end of the previous year, mainly due to the payment of 2020 annual bonuses[19]. - The company reduced its financial expenses by 50.61% year-on-year, primarily due to a decrease in loan scale and interest expenses[20]. - The company’s sales expenses rose by 58.8% year-on-year, reflecting increased marketing efforts following a period of reduced promotional activities due to the pandemic[20]. - Research and development expenses for Q1 2021 were ¥6,943,468.85, slightly down from ¥7,281,481.16 in Q1 2020, indicating a decrease of about 4.6%[46].

Financial Performance - Guanhao Biotech reported a revenue of CNY 500 million for the year 2020, representing a year-on-year increase of 20%[13]. - The company's operating revenue for 2020 was ¥436,957,168.89, a decrease of 0.21% compared to ¥437,886,453.72 in 2019[18]. - The net profit attributable to shareholders in 2020 was ¥46,594,900.23, a significant increase of 110.01% from a loss of ¥465,329,816.63 in 2019[18]. - Revenue for the reporting period was CNY 436.96 million, remaining stable compared to the previous year; operating profit rose by 109.24% to CNY 44.96 million; net profit attributable to shareholders increased by 110.01% to CNY 46.59 million[60]. - Total revenue for 2020 was ¥436,957,168.89, a slight decrease of 0.21% compared to ¥437,886,453.72 in 2019[74]. - The pharmaceutical segment reported revenue of 40.68 million yuan, representing a year-on-year growth of 193.60%, driven by the inclusion of the product Benimod in the national medical insurance directory[63]. Research and Development - The company plans to invest CNY 100 million in R&D for new regenerative medical products in 2021[13]. - The company is actively involved in the research and development of new drugs, with proprietary rights for the first-in-class drug Benvimod in the Greater China region[29]. - The company has established a national engineering laboratory for regenerative medical implants, focusing on innovative biomaterials and advanced medical technologies[29]. - The company is developing a world-class immune cell technology platform in collaboration with a leading academic team, focusing on stem cell research and clinical translation[30]. - The company is advancing several key R&D projects, including clinical trials for various medical products[87]. - The company has applied for 6 new invention patents and 1 utility model patent, increasing its total authorized patents to 115, including 91 invention patents[68]. Product Development and Innovation - The company has launched two new products in the regenerative medicine sector, contributing to 10% of total sales in 2020[13]. - The innovative drug Benvimod, a first-in-class treatment for inflammatory and autoimmune diseases, was included in the national medical insurance directory in 2020[153]. - The company is developing a new drug, "Benvimod," which is the first-in-class treatment for inflammatory and autoimmune diseases, marking a significant innovation in the pharmaceutical industry[50][55]. - The company has developed advanced original technology for new biomaterials, which may require significant market investment and longer cultivation periods, posing market risks[114]. - The company is focusing on expanding its product portfolio and market reach through strategic investments and product development[89]. Market Strategy and Expansion - Guanhao Biotech is targeting a revenue growth of 25% for 2021, with a projected revenue of CNY 625 million[13]. - The company is exploring potential acquisitions to enhance its market presence in Southeast Asia[13]. - The company aims to integrate resources across its three main platforms: biomedical materials, pharmaceuticals, and cell therapy, to enhance its market position in regenerative medicine[35]. - The company is actively seeking suitable acquisition targets in the regenerative medicine field to enhance its product line and achieve external growth[116]. - The company has established a comprehensive sales network across China, utilizing a multi-channel sales model that combines academic promotion and distribution[34]. Financial Management - The company has decided not to distribute cash dividends for the fiscal year 2020 to reinvest in growth opportunities[5]. - The company reported a significant reduction in financial expenses by 36.09% due to improved cash management and reduced loan amounts[84]. - The company’s cash dividend distribution policy was strictly followed, ensuring clarity and completeness in decision-making processes[122]. - The company reported a cumulative distributable profit of negative CNY 465.33 million as of the end of 2020, leading to no cash dividend distribution for the year[121]. Operational Efficiency - The company’s operating expenses increased by 5% in 2020, primarily due to higher marketing costs[13]. - The company is focusing on integrating and optimizing its business segments to enhance team collaboration and innovation[71]. - The company plans to enhance its marketing team and optimize organizational structure to improve resource sharing and talent development[71]. - The company has established a strict supplier evaluation system to mitigate risks related to animal epidemics affecting raw material supply[114]. Corporate Governance and Management - The company has a diverse board with members holding various academic and professional backgrounds, including management, finance, and medical expertise[186][187][188][189][190]. - The company emphasizes its commitment to innovation and research in the biotechnology sector, with key personnel involved in various scientific and medical research initiatives[187][189]. - The company has a strong emphasis on compliance and governance, with independent directors and experienced professionals overseeing its operations[188][190]. - The total remuneration for directors, supervisors, and senior management was CNY 7.0969 million for the reporting period[197]. Social Responsibility - The company donated 240 protective goggles valued at 300,000 RMB to Zhongshan University First Affiliated Hospital during the COVID-19 pandemic[154]. - The company provided rent reductions totaling nearly 2 million RMB to support businesses in its technology park from February 1 to February 29, 2020[154]. - The company has not engaged in targeted poverty alleviation work during the reporting period and has no subsequent plans[157]. Market Trends and Opportunities - The market for psoriasis treatment drugs is expected to grow from $6.6 billion in 2014 to $13.3 billion by 2024, representing a compound annual growth rate of 7.3%[40]. - The global stem cell therapy research market is anticipated to experience significant growth from 2019 to 2025, driven by emerging market consumption[44]. - China's pharmaceutical market is projected to grow at a rate of 14%-17%, exceeding 5.3 trillion yuan by 2025[39].

Financial Performance - Net profit attributable to shareholders was ¥9,893,955.37, representing an 81.74% increase year-over-year[8] - Operating income for the period was ¥115,439,961.86, up 4.43% from the same period last year[8] - Basic earnings per share increased to ¥0.04, a 100% rise compared to the previous year[8] - The company reported a net profit of ¥36,860,812.70 for the year-to-date, a significant increase of 162.55% compared to the same period last year[8] - The company's operating revenue for the current period is 55,897,711.74, an increase from 50,783,618.90 in the previous period[51] - Operating profit for the current period is 19,806,068.81, significantly up from 203,975.56 in the previous period[52] - Net profit for the current period is 16,390,918.04, compared to a net loss of 1,165,568.54 in the previous period[52] - The net profit attributable to the parent company is 36,860,812.70, up from 14,039,687.78 in the previous period[55] - Net profit for Q3 2020 reached CNY 9,368,685.99, compared to CNY 3,331,291.58 in the same period last year, representing an increase of approximately 181%[48] Cash Flow - Net cash flow from operating activities surged by 227.25% to ¥22,151,677.37[8] - Cash flow from operating activities increased by 24,043.49% year-on-year, attributed to reduced labor and expense costs due to the pandemic and increased government subsidies[23] - The net cash flow from operating activities was CNY 65,734,489.80, a turnaround from a negative cash flow of CNY -274,540.09 in the previous year[63] - Operating cash flow for the period reached ¥121,257,849.87, a significant increase from ¥17,577,898.33 in the previous period, representing a growth of approximately 590%[65] - The net cash flow from investing activities was CNY 140,225,444.30, a significant increase from CNY 30,194,619.59 in the previous year, indicating strong investment returns[64] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,328,234,576.14, an increase of 15.56% compared to the end of the previous year[8] - The company's total assets increased to CNY 1,523,974,831.05 from CNY 1,270,862,439.45, reflecting a growth of about 19.8%[44] - The total liabilities of the company as of September 30, 2020, were CNY 589,898,766.01, compared to CNY 445,211,628.42 at the end of 2019, reflecting an increase of around 32.4%[40] - Total liabilities rose to CNY 672,969,555.38, compared to CNY 452,332,547.19 in the previous period, indicating an increase of approximately 48.7%[44] - The company's current assets reached CNY 616,151,762.77, up from CNY 416,278,350.65 at the end of 2019, indicating a growth of about 47.9%[38] Shareholder Information - The total number of shareholders at the end of the reporting period was 36,452[12] - The largest shareholder, Guangdong Zhiguang Biotechnology Co., Ltd., held 20.76% of the shares[12] - The controlling shareholder Guangdong Zhiguang Biotech Co., Ltd. had 15,871,612 shares released from judicial freeze as of September 15, 2020, with no remaining frozen shares[26] Research and Development - Research and development expenses for Q3 2020 were CNY 6,986,468.66, down from CNY 8,267,888.06 year-over-year[47] - Research and development expenses increased to 2,186,466.78 from 1,942,798.28 in the previous period, reflecting a focus on innovation[51] - Research and development expenses increased to CNY 7,257,402.88 from CNY 6,535,573.64, reflecting the company's commitment to innovation[58] Compliance and Governance - The company committed to avoiding any business activities that may compete with its operations, ensuring compliance with relevant regulations[28] - The company has implemented measures to ensure fair and equitable treatment in related party transactions[29] - There were no violations regarding external guarantees during the reporting period[30] - There were no non-operating fund occupations by the controlling shareholder or its affiliates during the reporting period[31] Investment Activities - The company acquired a 31% stake in ZY Therapeutics Inc. from U.S. TIANYOU CAPITAL CORP for $3.1 million, completing the transfer and registration during the reporting period[26] - The company reported a significant reduction in financial expenses, down to 1,030,868.88 from 2,085,254.40 in the previous period[51] - The company recorded investment income of CNY 6,810,648.88, a significant improvement from a loss of CNY -654,099.78 in the previous year[58]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 203,611,983.94, a decrease of 1.96% compared to the same period last year[20]. - The net profit attributable to shareholders of the listed company increased by 213.72% to CNY 26,966,857.33 from CNY 8,595,700.79 in the previous year[20]. - The net profit after deducting non-recurring gains and losses reached CNY 19,628,680.96, a significant increase of 747.83% compared to a loss of CNY 3,029,898.03 in the same period last year[20]. - The net cash flow from operating activities was CNY 43,582,812.43, a remarkable increase of 718.76% from a negative cash flow of CNY 7,043,609.80 in the previous year[20]. - Basic earnings per share rose to CNY 0.10, reflecting a 233.33% increase from CNY 0.03 in the same period last year[20]. - Total profit for the period was CNY 33.99 million, a growth of 420.19% year-on-year[55]. - The total comprehensive income for the first half of 2020 was CNY 28,565,539.29, compared to a loss of CNY -2,960,141.65 in the previous year[152]. - The total profit for the first half of 2020 was CNY 33,997,802.25, compared to CNY 6,535,645.78 in the same period of 2019, marking an increase of 419.5%[154]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,178,545,628.47, an increase of 2.54% from CNY 1,149,347,790.02 at the end of the previous year[20]. - The total assets at the end of the reporting period were 1,317.8 million yuan, with a decrease of 7,951,000 yuan compared to the previous year[168]. - Total liabilities amounted to CNY 514,975,815.96, an increase from CNY 452,332,547.19 at the end of 2019, representing a rise of 13.9%[148]. - The company's equity attributable to shareholders increased to CNY 834,614,357.63 from CNY 818,529,892.26, marking a growth of 2.0%[148]. - The company's cash and cash equivalents at the end of the reporting period were 55.70 million yuan[169]. Market and Industry Insights - The global medical device market is valued at USD 405 billion, with an annual compound growth rate of approximately 5%[33]. - China's medical device market exceeded CNY 500 billion in 2017 and is projected to surpass CNY 900 billion by 2022, maintaining a growth rate of over 20%[33]. - The cataract incidence rate among individuals aged 60 to 89 in China is 80%, and over 90% for those aged 90 and above, indicating a significant market demand for artificial lenses[35]. - The domestic medical device market only accounts for 14% of the total pharmaceutical market, compared to 42% for foreign medical devices, suggesting substantial growth potential[35]. Research and Development - The company has established a "3+1" business structure, focusing on biomaterials, cells, pharmaceuticals, and a technology incubation platform[27]. - The company has developed a series of regenerative medical materials that are biocompatible and induce tissue growth, with products applicable in various medical fields[29]. - The company’s innovative drug, Benvimod, is used for treating autoimmune diseases and has shown significant advantages over existing products[29]. - The company has applied for 5 new invention patents and 1 utility model patent during the reporting period, bringing the total number of authorized patents to 96[61]. - Research and development expenses decreased by 21.56% to ¥17.64 million from ¥22.50 million year-on-year[66]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company is actively optimizing marketing channels and strategies in the biopharmaceutical sector to enhance sales performance[55]. - The company plans to enhance its market presence through academic promotion and collaboration with industry experts[85]. - The company is focused on developing new products using advanced biomaterials, aiming to create a pipeline of products in various stages of development, including clinical trials and market launch[87]. Corporate Governance - All directors attended the board meeting to review the report, ensuring the accuracy and completeness of the financial statements[5]. - The company is committed to avoiding competition with its own subsidiaries and ensuring fair practices in related transactions[94]. - The participation rate of investors in the 2020 first extraordinary general meeting was 18.91%, while the annual general meeting had a participation rate of 19.00%[92]. Financial Management - The company has established a strict supplier evaluation system to mitigate risks associated with potential animal epidemics that could disrupt raw material supply[88]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[104]. - The company has not conducted any major contracts or guarantees during the reporting period[112]. Compliance and Reporting - The financial report for the first half of 2020 was not audited[139]. - There were no major litigation or arbitration matters during the reporting period[99]. - The company has not experienced any penalties or rectification situations during the reporting period[100].